latest blog entries
Loading...
Branding...
latest headlines for company on cafepharma
Forbes
Tue, 05/07/13 - 11:31 am
tags: Alkermes, AstraZeneca, clinical depression, Lundbeck, Merck, Novartis, Pfizer, Sanofi
Seeking Alpha
Fri, 07/27/12 - 11:55 am
TheStreet.com
Mon, 07/23/12 - 9:15 am
tags: Alexion, Alkermes, Amarin, Amgen, Amylin, AstraZeneca, BiogenIdec, Bristol-Myers Squibb, Celgene, drug approvals, earnings, Eli Lilly, Gilead, GSK, Horizon Pharma, Human Genome Sciences, InterMune, Merck, Progenics Pharmaceuticals, Questcor, Regeneron, Roche, Salix, Sanofi, United Therapeutics
Seeking Alpha
Wed, 07/18/12 - 12:27 pm
Seeking Alpha
Sun, 07/15/12 - 11:22 am
Seeking Alpha
Thu, 07/12/12 - 10:58 am
tags: Alkermes, Arena Pharmaceuticals, Orexigen, Questcor, Vivus
Seeking Alpha
Tue, 06/12/12 - 1:11 pm
tags: Alkermes, Arena Pharmaceuticals, Orexigen, Questcor, Vivus
Seeking Alpha
Mon, 06/11/12 - 11:26 am
Yahoo/Business Wire
Sat, 06/09/12 - 12:34 pm
tags: Alkermes, Amylin, Bydureon, diabetes, type 2 diabetes
Yahoo/Business Wire
Sat, 06/09/12 - 12:33 pm
tags: Alkermes, Amylin, Bydureon, diabetes, type 2 diabetes
Pharma Times, UK
Wed, 03/14/12 - 9:45 am
Seeking Alpha
Tue, 02/21/12 - 8:19 pm
Fierce Pharma
Mon, 01/30/12 - 5:00 pm
Last 30 twitter posts
-
(ALKS) Alkermes t.co/TDMGlPF4UB
-
"@MikeEisenbergMD: $ALKS rockets off 50MA twice in a 5 wks! Extended? IBD earnings summary t.co/PQuuyDilQh t.co/K31ccqPZYh"
-
投行观点：MKM Partners将Alkermes Plc 评级从中性下调至卖出: 以上为即时重要消息提示，路透中文快讯将暂不做进一步报导。 t.co/7s8I1mJGlo
-
Alkermes Posts 4Q Profit As Royalty Payments Rise t.co/qQj5GT6Byy #Pharmalive t.co/zVyVopwbvW
-
Alkermes Posts 4Q Profit As Royalty Payments Rise t.co/38uQMN0DRG #Pharmalive
-
Alkermes Posts 4Q Profit As Royalty Payments Rise t.co/qQj5GT6Byy #Pharmalive
-
Alkermes Posts 4Q Profit As Royalty Payments Rise t.co/sCT6HDSLhb #Pharmalive t.co/gj8eSEdc9e
-
Alkermes $ALKS was downgraded by analysts at MKM Partners to a "sell" rating. t.co/K4kIrWhD2U
-
Alkermes plc Reports Financial Results for Fiscal Year 2013 and Provides ... - Business Wire (press release) t.co/DoOwzknaqb
-
Alkermes Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference t.co/GPspTd2QMi
-
Alkermes Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference t.co/0mGE56c17R
-
RT @IBDinvestors: Alkermes Earnings Beat Estimates, But Outlook Unclear t.co/p3KMnfPswu
-
Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conferenc... t.co/RPqRXvBvPu
-
Alkermes turns a loss into a gain -- t.co/qOtmMnVHb9
-
Alkermes turns a loss into a gain -- t.co/AIBJrvHBAS
-
Alkermes Earnings Beat Estimates, But Outlook Unclear t.co/TA4x3uUiNx #Stocks
-
Alkermes Earnings Beat Estimates, But Outlook Unclear t.co/p3KMnfPswu
-
Alkermes $ALKS shares took a wild ride after earns. Analyst says move to new fiscal year cause confusion. t.co/lYDJtTrSID
-
Alkermes Earnings Beat Estimates, But Outlook Unclear t.co/LIbjkFjXtA
-
Alkermes Earnings Beat Estimates, But Outlook Unclear: t.co/EP9BA1d6ve
-
NASDAQ Active Stock Watch List: Apricus Biosciences, Inc. (NASDAQ:APRI ...: NASDAQ Active Stock Watch List: Ap... t.co/Obk7dq3x0j
-
Alkermes moves into profit as Elan delivers t.co/RD9Czsf8H8
-
Alkermes posts fourth quarter gains, changes fiscal year t.co/x4QXjKMpFB
-
Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference t.co/1UwAApEzG0
-
Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference t.co/wwxFWcZLwN
-
Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference t.co/PKWIR0mX2w
-
Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conferenc t.co/rvNZiIp952
-
$ALKS Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Ann.. t.co/7c0fd6BVC7
-
Alkermes posts 4Q profit as royalty payments rise t.co/b3LC3zTdxC
Latest Health Message Board Posts
... suicidal thoughts and behaviors, although the treatment will not include any boxed warnings. According to drugmaker Alkermes, about 10,000 patients a year currently use extended-release naltrexone to treat alcohol dependence, a treatment strategy approved ...
Posted by:
nygirl7
at
2010-10-13 05:00:00
on
medhelp.org
... one time Daily injection. Amlyn's Bydureon scheduled for approval in Oct by the FDA, is Basically the Byetta with technology from Alkermes. The base for both byetta and bydureon come from the sliva of the Gila Monster (go figure). Bydureon is scheduled for ...
Posted by:
PrettynPurple
at
2010-06-23 18:55:00
on
diabetesforums.com
... , others rise on Byetta news Bloomberg News SAN FRANCISCO � Amylin Pharmaceuticals Inc. and Waltham, Mass.-based Alkermes Inc. climbed in Nasdaq trading yesterday after regulators said they do not need more studies for a once-weekly version of the ... States and co-markets it with Amylin in the United States. The drug was developed by Amylin, and the longer-acting technology was developed by Alkermes.
Posted by:
mimmie2010
at
2010-03-16 05:46:00
on
diabetesforums.com